133 related articles for article (PubMed ID: 12529678)
1. Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma.
Niitsu N; Honma Y; Iijima K; Takagi T; Higashihara M; Sawada U; Okabe-Kado J
Leukemia; 2003 Jan; 17(1):196-202. PubMed ID: 12529678
[TBL] [Abstract][Full Text] [Related]
2. Serum nm23-H1 protein as a prognostic factor in hematological malignancies.
Okabe-Kado J
Leuk Lymphoma; 2002 Apr; 43(4):859-67. PubMed ID: 12153176
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of the nm23-H1 protein and their clinical implication in extranodal NK/T-cell lymphoma.
Niitsu N; Okamoto M; Honma Y; Nakamine H; Tamaru JI; Nakamura S; Yoshino T; Higashihara M; Hirano M; Okabe-Kado J;
Leukemia; 2003 May; 17(5):987-90. PubMed ID: 12750720
[No Abstract] [Full Text] [Related]
4. nm23-H1 protein expression and gene mutation in 150 patients with non-Hodgkin's lymphomas.
Lee JH; Cho SJ; Zhang X; Zheng Z; Lee ES; Kim A; Kim YS; Chae YS; Kim I
J Korean Med Sci; 2006 Aug; 21(4):645-51. PubMed ID: 16891807
[TBL] [Abstract][Full Text] [Related]
5. Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness.
Aryee DN; Simonitsch I; Mosberger I; Kos K; Mann G; Schlögl E; Pötschger U; Gadner H; Radaszkiewicz T; Kovar H
Br J Cancer; 1996 Dec; 74(11):1693-8. PubMed ID: 8956779
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma.
Niitsu N; Okabe-Kado J; Kasukabe T; Yamamoto-Yamaguchi Y; Umeda M; Honma Y
Blood; 1999 Nov; 94(10):3541-50. PubMed ID: 10552965
[TBL] [Abstract][Full Text] [Related]
7. Expression of nm23-H1 in transitional cell carcinoma of the upper urinary tract.
Cheng HL; Tong YC; Tzai TS; Weng CL; Ho CL; Yang WH; Lin JS; Chow NH
Oncol Rep; 2001; 8(1):193-6. PubMed ID: 11115597
[TBL] [Abstract][Full Text] [Related]
8. [Serum levels of mm23-H1 protein and their clinical implications in malignant lymphoma].
Niitsu N
Rinsho Ketsueki; 2001 Dec; 42(12):1155-61. PubMed ID: 11828717
[No Abstract] [Full Text] [Related]
9. Immunohistochemical analysis of nm23-H1 in stage I non-small cell lung cancer: a useful marker in prediction of metastases.
Lai WW; Wu MH; Yan JJ; Chen FF
Ann Thorac Surg; 1996 Nov; 62(5):1500-4. PubMed ID: 8893591
[TBL] [Abstract][Full Text] [Related]
10. Expression of p16, nm23-H1, E-cadherin, and CD44 gene products and their significance in nasopharyngeal carcinoma.
Huang GW; Mo WN; Kuang GQ; Nong HT; Wei MY; Sunagawa M; Kosugi T
Laryngoscope; 2001 Aug; 111(8):1465-71. PubMed ID: 11568585
[TBL] [Abstract][Full Text] [Related]
11. Nm23-H1 protein, DNA-ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder.
Alderisio M; Cenci M; Valli C; Russo A; Bazan V; Dardanoni G; Cucciarre S; Carreca I; Macaluso MP; Tomasino RM; Vecchione A
Anticancer Res; 1998; 18(6A):4225-30. PubMed ID: 9891471
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays.
Charpin C; Garcia S; Bonnier P; Martini F; Andrac L; Horschowski N; Lavaut MN; Allasia C
J Pathol; 1998 Apr; 184(4):401-7. PubMed ID: 9664906
[TBL] [Abstract][Full Text] [Related]
13. Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma.
Niitsu N; Nakamine H; Okamoto M; Akamatsu H; Honma Y; Higashihara M; Okabe-Kado J; Hirano M;
Br J Haematol; 2003 Nov; 123(4):621-30. PubMed ID: 14616965
[TBL] [Abstract][Full Text] [Related]
14. The role of nm23-H1 in the progression of transitional cell bladder cancer.
Chow NH; Liu HS; Chan SH
Clin Cancer Res; 2000 Sep; 6(9):3595-9. PubMed ID: 10999750
[TBL] [Abstract][Full Text] [Related]
15. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma.
Srivatsa PJ; Cliby WA; Keeney GL; Dodson MK; Suman VJ; Roche PC; Podratz KC
Gynecol Oncol; 1996 Mar; 60(3):363-72. PubMed ID: 8774640
[TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of nm23-H1 and MUC-1 in peripheral T-cell lymphoma].
Huang HQ; Pan ZH; Lin XB; Wang BF; Hou JH; Zhang Y; Wu QL
Ai Zheng; 2006 Dec; 25(12):1517-23. PubMed ID: 17166378
[TBL] [Abstract][Full Text] [Related]
17. [Study on expression of nm23-H1 protein/NDPK-A in laryngeal carcinoma].
Li J; Jin K; Yin S
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 1998 Jun; 12(6):247-50. PubMed ID: 11189167
[TBL] [Abstract][Full Text] [Related]
18. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.
Heimann R; Lan F; McBride R; Hellman S
Cancer Res; 2000 Jan; 60(2):298-304. PubMed ID: 10667580
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome.
Ito Y; Okabe-Kado J; Honma Y; Iwase O; Shimamoto T; Ohyashiki JH; Ohyashiki K
Leukemia; 2002 Feb; 16(2):165-9. PubMed ID: 11840281
[TBL] [Abstract][Full Text] [Related]
20. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma.
Niitsu N; Okabe-Kado J; Okamoto M; Takagi T; Yoshida T; Aoki S; Hirano M; Honma Y
Blood; 2001 Mar; 97(5):1202-10. PubMed ID: 11222361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
